You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中關村(000931.SZ):山東華素收到鹽酸貝尼地平變更登記事項的受理通知書
格隆匯 06-01 20:15

格隆匯6月1日丨中關村(000931.SZ)公告,近日,北京中關村科技發展(控股)股份有限公司(以下簡稱:公司)全資子公司北京中關村四環醫藥開發有限責任公司之控股子公司北京華素製藥股份有限公司之全資子公司山東華素製藥有限公司(以下簡稱:山東華素)收到國家藥品監督管理局(以下簡稱:國家藥監局)簽發的鹽酸貝尼地平變更登記事項《受理通知書》。截止公告日,鹽酸貝尼地平原料藥項目已累計投入研發費用571萬元。

山東華素將積極協助國家藥監局進行鹽酸貝尼地平變更的審評工作。公司高度重視藥品研發,並嚴格控制藥品研發、製造及銷售環節的質量及安全。由於醫藥產品具有高科技、高風險、高附加值的特點,藥品銷售容易受國家政策、市場環境等因素的影響,具有較大不確定性,敬請廣大投資者謹慎決策,注意防範投資風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account